Abstract:Context Gastric bypass (GBP) and sleeve gastrectomy (SG) are both effective bariatric treatments that cause sustained weight loss as well as improvement of type 2 diabetes mellitus (T2DM). The underlying mechanisms are under investigation, including the contribution of alterations in bile acids (BAs) in achieving or maintaining the beneficial metabolic effects after bariatric surgery. Aims The aim of this study is to investigate the acute and short-term effects of GBP and SG on BA compositions and fibroblast growth factor 19 (FGF19) in obese individuals with T2DM and to evaluate any correlations between changes in these measures with glucose metabolic improvements. Methods The levels of both fasting and postprandial plasma BA compositions after oral glucose tolerance test (OGTT), fasting FGF19 and various metabolic indices were measured 1 day before and at 3 days and 3 months after GBP and SG in 19 obese patients (GBP = 8, SG = 11) with T2DM. Results Body weight loss was observed after both GBP and SG 3 months post-operatively, with no significant difference between the two intervention groups (15.0 ± 3.1% vs. 13.9 ± 5.2%, P = 0.761). At 3 days post-operation, FGF19 levels increased significantly in both surgery groups (GBP, 118.3 ± 57.3 vs. 363.6 ± 131.0 pg mL −1 , post-operation P = 0.008; SG, 173.2 ± 127.8 vs. 422.0 ± 243.6 pg mL −1 , post-operation P = 0.001). Fasting and postprandial increases from pre-operative values in secondary ( r = 0.57, P = 0.02; r = 0.58, P = 0.01), conjugated ( r = 0.50, P = 0.01; r = 0.48, P = 0.04), glycine-conjugated ( r = 0.52, P = 0.05; r = 0.46, P = 0.05) and secondary-conjugated ( r = 0.53, P = 0.02; r = 0.60, P = 0.01) BAs correlated with decreases in the postprandial states of glucose (defined by area under the curve (AUC) over 120 min (AUC 0-120min )). Increases in postprandial primary-conjugated BAs were found to be associated with decreases in HOMA-IR ( r = 0.45, P = 0.05). However, increases in fasting and postprandial taurine-conjugated BA correlated with decreases in both basal insulin secretion rate ( r = 0.47, P = 0.04; r = 0.48, P = 0.04) and C-peptide level ( r = 0.45, P = 0.05; r = 0.47, P = 0.04). After 3 months, fasting and postprandial increases in secondary ( r = 0.51, P = 0.03; r = 0.48, P = 0.04), secondary-conjugated ( r = 0.52, P = 0.02; r = 0.51, P = 0.03) and non-12α-OH ( r = 0.51, P = 0.02; r = 0.58, P = 0.01) BAs were found to correlate with increases in Stumvoll Insulin Sensitivity Index. Increases in both fasting and postprandial 12α-OH BAs were correlated with the decreases in glucose AUC ( r = 0.46, P = 0.05; r = 0.41, P = 0.04). Conclusions Both GBP and SG achieve increases in many BA species as early as 3 days post-operation, which are sustained at 3 months post-operation. Rises in secondary BA and conjugated forms are correlated with early improvements in glucose metabolism at 3 days post-operation. These along with 12α-OH BA correlated with improved glucose metabolism at 3 months post-operation, suggesting they may contribute to the observed T2DM remission after bariatric surgery.

Vagal activation alters prandial bile acid composition and glycemia in patients with hypoglycemia after Roux‐en‐Y gastric bypass surgery

Chenodeoxycholic Acid As a Potential Prognostic Marker for Roux-en-Y Gastric Bypass in Chinese Obese Patients.

Acute Changes of Bile Acids and FGF19 After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass

Gastric bypass alters both glucose-dependent and glucose-independent regulation of islet hormone secretion

In vivo mapping of postprandial hepatic glucose metabolism using dynamic magnetic resonance spectroscopy combined with stable isotope flux analysis in Roux‐en‐Y gastric bypass adults and non‐operated controls: A case–control study

Post-prandial hypoglycemia results from a non-glucose-dependent inappropriate insulin secretion in Roux-en-Y gastric bypassed patients

Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia in Patients With Obesity and Prediabetes or Type 2 Diabetes: A Prospective Cohort Study

Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission.

Roux-en-Y gastric bypass-induced perturbative changes in microbial communities and metabolic pathways in rats

Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis

The Effects of Calorie Restriction and Bariatric Surgery on Circulating Proneurotensin Levels

Predictive Value of Gut Peptides in T2D Remission: Randomized Controlled Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrectomy and Greater Curvature Plication

Metabolic Effects and Safety of Roux‐en‐Y Gastric Bypass Surgery Vs. Conventional Medication in Obese Chinese Patients with Type 2 Diabetes

Gut peptides before and following Roux‐En‐Y gastric bypass: A systematic review and meta‐analysis

Changes in Bile Acid Metabolism, Transport, and Signaling as Central Drivers for Metabolic Improvements After Bariatric Surgery

Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats

Contribution of glycemic variability to hypoglycemia, and a new marker for diabetes remission after Roux-en-Y gastric bypass surgery

Increased glycemic variability in pregnant women with Roux-en-Y gastric bypass compared with sleeve gastrectomy

Gut microbiota after Roux-en-Y gastric bypass and sleeve gastrectomy in a diabetic rat model: Increased diversity and associations of discriminant genera with metabolic changes

Endocannabinoid Receptor-1 and Sympathetic Nervous System Mediate the Beneficial Metabolic Effects of Gastric Bypass

Lower ghrelin levels does not impact the metabolic benefit induced by Roux-en-Y gastric bypass